[go: up one dir, main page]

EA200801000A1 - Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf) - Google Patents

Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)

Info

Publication number
EA200801000A1
EA200801000A1 EA200801000A EA200801000A EA200801000A1 EA 200801000 A1 EA200801000 A1 EA 200801000A1 EA 200801000 A EA200801000 A EA 200801000A EA 200801000 A EA200801000 A EA 200801000A EA 200801000 A1 EA200801000 A1 EA 200801000A1
Authority
EA
Eurasian Patent Office
Prior art keywords
corticotropine
crf
pyrazolo
pyrimidyl
antagonists
Prior art date
Application number
EA200801000A
Other languages
English (en)
Inventor
Франк Хосснер
Original Assignee
Эс Би ФАРМКО ПУЭРТО РИКО ИНК.
Ньюрокрайн Байосайенсиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801000(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эс Би ФАРМКО ПУЭРТО РИКО ИНК., Ньюрокрайн Байосайенсиз Инк. filed Critical Эс Би ФАРМКО ПУЭРТО РИКО ИНК.
Publication of EA200801000A1 publication Critical patent/EA200801000A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к полиморфной форме 2 [3-(4-метокси-2-метилфенил)-2,5-диметилпиразоло[1,5-a]пиримидин-7-ил]-[(S)-1-(3-метил[1,2,4]оксадиазол-5-ил)пропил]амина. Настоящее изобретение также относится к фармакологической композиции, содержащей данное соединение, и способам его применения.
EA200801000A 2005-09-30 2006-09-28 Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf) EA200801000A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound
PCT/US2005/037576 WO2006044958A1 (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists
PCT/EP2006/009531 WO2007039264A1 (en) 2005-09-30 2006-09-28 Pyrazolo [1, 5 -alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists

Publications (1)

Publication Number Publication Date
EA200801000A1 true EA200801000A1 (ru) 2009-02-27

Family

ID=35395069

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801000A EA200801000A1 (ru) 2005-09-30 2006-09-28 Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)

Country Status (21)

Country Link
US (1) US7879862B2 (ru)
EP (2) EP1802627B1 (ru)
JP (2) JP4901744B2 (ru)
KR (2) KR20070088621A (ru)
CN (1) CN101273043B (ru)
AR (2) AR051461A1 (ru)
AU (2) AU2005295353B2 (ru)
BR (1) BRPI0616767A2 (ru)
CA (2) CA2584567C (ru)
CR (1) CR9918A (ru)
EA (1) EA200801000A1 (ru)
GB (1) GB0519957D0 (ru)
IL (1) IL190225A0 (ru)
MA (1) MA29850B1 (ru)
NO (2) NO20072541L (ru)
NZ (1) NZ554082A (ru)
PE (2) PE20060586A1 (ru)
RU (1) RU2007118683A (ru)
TW (2) TW200626599A (ru)
UA (1) UA92756C2 (ru)
WO (2) WO2006044958A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7737154B2 (en) * 2003-12-22 2010-06-15 Smithkline Beecham (Cork) Limited CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101932583A (zh) 2007-12-19 2010-12-29 沃泰克斯药物股份有限公司 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
PL2266990T3 (pl) 2008-04-15 2013-03-29 Eisai R&D Man Co Ltd ZWIĄZEK 3-FENYLOPIRAZOLO[5,1-b] TIAZOLOWY
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011043387A1 (ja) * 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) * 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
HUE068315T2 (hu) 2014-01-21 2024-12-28 Neurocrine Biosciences Inc CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére
AU2015208205B2 (en) * 2014-01-22 2019-12-05 Curovir Ab Pyrazolo[1,5-a]pyrimidines as antiviral compounds
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
HRP20251224T1 (hr) 2018-12-07 2025-12-19 Neurocrine Biosciences, Inc. Antagonist crf1 receptora, farmaceutski pripravci i njihovi čvrsti oblici za liječenje kongenitalne adrenalne hiperplazije
JP2022543106A (ja) 2019-07-30 2022-10-07 エイコニゾ セラピューティクス，インコーポレーテッド Ｈｄａｃ６インヒビターおよびそれらの使用
EP4034111A1 (en) 2019-09-27 2022-08-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
WO2022093904A1 (en) * 2020-10-27 2022-05-05 Trevena, Inc. Crystalline and amorphous forms of a delta-opioid modulator
MX2023012875A (es) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
PT880523E (pt) 1996-02-07 2007-01-31 Neurocrine Biosciences Inc Pirazolopirimidinas com antagonistas dos receptores de crf
EE04316B1 (et) * 1996-07-24 2004-06-15 Dupont Pharmaceuticals Company Asolotriasiinid ja -pürimidiinid, neid sisaldavadfarmatseutilised kompositsioonid ning nende kasutamine ravimite valmistamiseks
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
CA2614603C (en) * 1998-01-28 2011-08-16 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
CA2359041A1 (en) 1999-01-29 2000-08-03 Sumitomo Chemical Co., Ltd. Fat accumulation inhibitory agents
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2001023387A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
KR20020047201A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 아미노-치환된 피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
ES2301633T3 (es) * 2001-04-30 2008-07-01 Glaxo Group Limited Pirimidinas condensadas como antagonistas del factor de liberacion de corticotropina (crf).
EP1395591B1 (en) * 2001-06-12 2008-06-04 Glaxo Group Limited Corticotropin releasing factor antagonists
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US20070066640A1 (en) * 2003-01-16 2007-03-22 Emiliano Castiglioni Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
US7737154B2 (en) * 2003-12-22 2010-06-15 Smithkline Beecham (Cork) Limited CRF receptor antagonists and methods relating thereto
WO2005063756A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
ATE430746T1 (de) * 2004-10-19 2009-05-15 Smithkline Beecham Cork Ltd Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
BRPI0616767A2 (pt) 2011-06-28
AU2005295353B2 (en) 2012-01-12
PE20060586A1 (es) 2006-09-20
CN101273043B (zh) 2011-08-03
TW200745121A (en) 2007-12-16
EP1934222B1 (en) 2012-07-25
CA2584567C (en) 2013-04-30
NO20081941L (no) 2008-04-23
EP1802627A1 (en) 2007-07-04
AU2006298995A1 (en) 2007-04-12
EP1934222A1 (en) 2008-06-25
CN101273043A (zh) 2008-09-24
AR051461A1 (es) 2007-01-17
CR9918A (es) 2009-02-03
US20080194589A1 (en) 2008-08-14
TW200626599A (en) 2006-08-01
JP4901744B2 (ja) 2012-03-21
EP1802627B1 (en) 2012-08-29
CA2584567A1 (en) 2006-04-27
AU2006298995B2 (en) 2012-06-14
NO20072541L (no) 2007-06-25
KR20070088621A (ko) 2007-08-29
AU2005295353A1 (en) 2006-04-27
WO2006044958A1 (en) 2006-04-27
UA92756C2 (ru) 2010-12-10
US7879862B2 (en) 2011-02-01
CA2624699A1 (en) 2007-04-12
GB0519957D0 (en) 2005-11-09
JP2009510004A (ja) 2009-03-12
WO2007039264A1 (en) 2007-04-12
AR056104A1 (es) 2007-09-19
MA29850B1 (fr) 2008-10-03
KR20080063760A (ko) 2008-07-07
WO2006044958A8 (en) 2006-06-08
JP2008517067A (ja) 2008-05-22
NZ554082A (en) 2010-12-24
RU2007118683A (ru) 2008-11-27
IL190225A0 (en) 2009-09-22
PE20070845A1 (es) 2007-08-25

Similar Documents

Publication Publication Date Title
EA200801000A1 (ru) Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
CO5560547A2 (es) Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasa
ATE421967T1 (de) Nichtvernetzende pyrroloä2,1-cüä1, 4übenzodiazepine als potentielle antitumor- agentien und ihre herstellung
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
EA201170771A1 (ru) Органические соединения
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
KR20100014397A (ko) 아데노신 에이투에이 수용체 길항제
MX2013004681A (es) Inhibidores de cdk.
JPWO2005026126A1 (ja) Ｃｒｆ拮抗剤および二環式複素環化合物
UA98966C2 (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
WO2010011546A3 (en) Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
AR051395A1 (es) Derivados de imidazo- benzodiazepina, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos, y usos en terapeutica
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
DE60332874D1 (de) Pyren-gebundene pyrrolo(2,1-c)(1,4)benzodiazepin-derivate zur verwendung als antikrebsmittel
TW200942546A (en) A crystalline form of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one
TW200504074A (en) 7-substituted 3-nitro-pyrazolo[1,5-a]pyrimidines and compositions and methods related thereto
Martins et al. The structure in the solid state and in solution of 3 (5)-trifluoromethyl-4, 5 (3)-polymethylenepyrazoles
EA201001278A1 (ru) Способ получения оланзапина
TH79587A (th) อนุพันธ์ของอิมิดาโซ-เบนโซไดอะซีพีน
TNSN05325A1 (en) N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO